Search Result

Isoforms Recommended:	nNOS

Results for "

nNOS

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Amyloid-β (2) Apoptosis (1) Calcineurin (1) Calmodulin (1) CaMK (1) Caspase (1) Endogenous Metabolite (2) Histamine Receptor (1) HSP (1) IFNAR (1) iGluR (8) Interleukin Related (1) Isotope-Labeled Compounds (1) NO Synthase (51) Orthopoxvirus (2) P2X Receptor (1) Phosphorylase (1) Proteasome (1) Reactive Oxygen Species (ROS) (1) Reference Standards (7) Serine Racemase (SR) (1) Serotonin Transporter (3) Small Interfering RNA (siRNA) (2)
By Research Areas:	Cancer (13) Cardiovascular Disease (10) Endocrinology (3) Infection (2) Inflammation/Immunology (8) Metabolic Disease (5) Neurological Disease (41)
Oligonucleotides:	Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (2)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-18732A

L-NMMA acetate 10+ Cited Publications Tilarginine acetate; Methylarginine acetate	NO Synthase Endogenous Metabolite	Cardiovascular Disease Cancer
L-NMMA acetate is a nitric oxide synthase inhibitor of all NOS isoforms including NOS1, NOS2, and NOS3. The K_i values for nNOS (rat), eNOS (human), and iNOS (mouse) are approximately 0.18, 0.4, and 6 μM, respectively.

HY-100986

L-NIO dihydrochloride 1 Publications Verification	NO Synthase	Cardiovascular Disease
L-NIO dihydrochloride is a potent, non-selective and NADPH-dependent nitric oxide synthase (NOS) inhibitor, with K_is of 1.7, 3.9, 3.9 μM for neuronal (nNOS), endothelial (eNOS), and inducible (iNOS), respectively . L-NIO dihydrochloride induces a consistentfocal ischemic infarctin rats .

HY-14602

Tramiprosate 2 Publications Verification Homotaurine; 3-Amino-1-propanesulfonic acid	Amyloid-β	Cardiovascular Disease Cancer
Tramiprosate (Homotaurine), an orally active and brain-penetrant natural amino acid found in various species of red marine algae. Tramiprosate binds to soluble Aβ and maintains Aβ in a non-fibrillar form. Tramiprosate is also a GABA analog and possess neuroprotection, anticonvulsion and antihypertension effects .

HY-148417

ZZL-7	Serotonin Transporter	Neurological Disease
ZZL-7 is a fast-onset antidepressant agent. ZZL-7 works by disrupting the interaction between the serotonin transporter (SERT) and neuronal nitric oxide synthase (nNOS) in the dorsal raphe nucleus (DRN). ZZL-7 can cross the blood-brain barrier readily. ZZL-7 can be used for the research of major depressive disorder (MDD) .

HY-69019

7-Nitroindazole 1 Publications Verification	NO Synthase	Cardiovascular Disease Neurological Disease
7-Nitroindazole is a selective and BBB-penetrable inhibitor of nitric oxide synthase (NOS) (IC₅₀ = 0.47 μM in mouse cerebellum). 7-Nitroindazole does not affect blood pressure or endothelium-dependent relaxation while inhibiting nNOS in experimental animals. 7-Nitroindazole has anti-injurious and neuroprotective properties, and can be studied in research for neurological diseases such as Parkinson’s disease .

HY-W003969

Aminopicoline Ascensil; 2-Amino-4-methylpyridine	NO Synthase	Inflammation/Immunology
Aminopicoline (Ascensil) is a potent and non-selective inhibitor of nitric oxide synthase (NOS) isoenzymes (iNOS, nNOS, eNOS). Aminopicoline competes with arginine at the substrate-binding site of nitric oxide synthase, reduces cellular nitric oxide production, inhibits the elevation of plasma nitrate, increases mean arterial pressure at high doses, and also serves as a basis for radiolabeled ligands to localize nitric oxide synthase binding sites. Aminopicoline can be used in the research of diseases associated with septic shock, joint inflammation, intestinal inflammation, and CNS inflammation .

HY-12119

GW274150 2 Publications Verification	NO Synthase	Neurological Disease Inflammation/Immunology
GW274150 is a potent, selective, orally active and NADPH-dependent inhibitor of human inducible nitric oxide synthase (iNOS) (IC₅₀=2.19 μM; K_d=40 nM) and rat iNOS (ED₅₀=1.15 μM). GW274150 also displays less potency for both humans or rats endothelial NOS (eNOS) and neuronal NOS (nNOS). GW274150 exerts a protective role in an acute model of lung injury inflammation .

HY-P0117

Tat-NR2B9c 5+ Cited Publications Tat-NR2Bct; NA-1	iGluR NO Synthase	Neurological Disease
Tat-NR2B9c (Tat-NR2Bct; NA-1) is a postsynaptic density-95 (PSD-95) inhibitor, with EC₅₀ values of 6.7 nM and 670 nM for PSD-95d2 (PSD-95 PDZ domain 2) and PSD-95d1, respectively. Tat-NR2B9c disrupts the PSD-95/NMDAR interaction, inhibiting NR2A and NR2B binding to PSD-95 with IC₅₀ values of 0.5 μM and 8 μM, respectively. Tat-NR2B9c also inhibits neuronal nitric oxide synthase (nNOS)/PSD-95 interaction, and possesses neuroprotective efficacy .

HY-B0503

2-Thiouracil 2 Publications Verification Thiouracil	NO Synthase	Endocrinology Cancer
2-Thiouracil (Thiouracil) is a selective neuronal nitric oxide synthase (nNOS) inhibitor with a K_i value of 20 μM. 2-Thiouracil antagonizes BH4-induced nNOS dimerization. 2-Thiouracil is also an antithyroid compound and a highly specific melanoma detector. 2-Thiouracil stimulates the growth of pea and corn root segments .

HY-100456

ZL006 2 Publications Verification	iGluR	Neurological Disease
ZL006 is a potent inhibitor of nNOS/PSD-95 interaction, and inhibits NMDA receptor-mediated NO synthesis.

HY-18732

L-NMMA Maximum Cited Publications 11 Publications Verification Tilarginine; Methylarginine	NO Synthase	Neurological Disease Inflammation/Immunology Cancer
L-NMMA (Tilarginine) is a non-selective and competitive inhibitor of nitric oxide synthase. L-NMMA inhibits three subtypes, namely *nNOS, eNOS, and iNOS*, and reduces NO production . L-NMMA alleviates mechanical allodynia, thermal hyperalgesia, and choroidal fibrosis. L-NMMA is applicable to research related to nociception, bone cancer pain, and myopia .

HY-108615

CP-316819 GPi 819	Phosphorylase	Cardiovascular Disease Neurological Disease Metabolic Disease
CP-316819 (GPi 819) is a blood-brain barrier permeable glycogen phosphorylase inhibitor. CP-316819 inhibits hepatic glycogenolysis, safely reduces blood glucose in type 2 diabetes, and rarely induces hypoglycemia. CP-316819 increases brain glycogen reserves, protects neurons, alleviates hypoglycemic brain injury, and inhibits excessive platelet activation, exerting both neuroprotective and vasculoprotective effects. CP-316819 can be used in research related to hypoglycemia, thrombosis, autoimmune inflammatory diseases, and type 2 diabetes .

HY-B1478

Dimaprit dihydrochloride	Histamine Receptor NO Synthase	Endocrinology
Dimaprit dihydrochloride is a selective histamine H2 receptor agonist, it also inhibits *nNOS* with an IC₅₀ of 49 μM. Dimaprit dihydrochloride can stimulate gastric acid secretion .

HY-100457

IC87201 2 Publications Verification	iGluR	Neurological Disease
IC87201, an inhibitor of PSD95-nNOS protein-protein interactions, suppresses NMDAR-dependent NO and cGMP formation.

HY-18399

YM-1 1 Publications Verification	HSP NO Synthase	Cancer
YM-1 is a stable MKT-077 (HY-15096) analog and an orally active Hsp70 inhibitor. YM-1 induces cell death of HeLa cells and up-regulates the level of p53 and p21 proteins .

HY-12119A

GW274150 phosphate 2 Publications Verification	NO Synthase	Neurological Disease Inflammation/Immunology
GW274150 phosphate is a potent, selective, orally active and NADPH-dependent inhibitor of human inducible nitric oxide synthase (iNOS) (IC₅₀=2.19 μM; K_d=40 nM) and rat iNOS (ED₅₀=1.15 μM). GW274150 phosphate displays less potency for both humans or rats endothelial NOS (eNOS) and neuronal NOS (nNOS). GW274150 phosphate exerts a protective role in an acute model of lung injury inflammation .

HY-102062A

Nω-Propyl-L-arginine hydrochloride 1 Publications Verification N-omega-Propyl-L-arginine hydrochloride	NO Synthase	Neurological Disease
Nω-Propyl-L-arginine (N-omega-Propyl-L-arginine) hydrochloride is a potent, competitive, and highly selective inhibitor of neuronal nitric oxide synthase *(nNOS), with a K_i* of 57 nM. Nω-Propyl-L-arginine hydrochloride displays a 149-fold selectivity for nNOS over endothelial NOS (eNOS) .

HY-102062

Nω-Propyl-L-arginine 1 Publications Verification N-omega-Propyl-L-arginine	NO Synthase	Neurological Disease
Nω-Propyl-L-arginine (N-omega-Propyl-L-arginine) is a potent, competitive, and highly selective inhibitor of neuronal nitric oxide synthase *(nNOS), with a K_i* of 57 nM. Nω-Propyl-L-arginine displays a 149-fold selectivity for nNOS over endothelial NOS (eNOS) .

HY-12115

NG-nitro-L-arginine Nω-nitro-L-arginine; L-NOARG; L-NG-Nitroarginine	NO Synthase	Cardiovascular Disease
NG-nitro-L-arginine (Nω-nitro-L-arginine) is a NO Synthase inhibitor, with K_is of 0.61 μM (nNOS), 4.28 μM (iNOS), 0.72 μM (eNOS) respectively. NG-nitro-L-arginine inhibits endothelium-derived relaxing factor (EDRF) formation and release. NG-nitro-L-arginine inhibits portal-systemic shunting in portal-hypertensive rats, and increases blood pressure .

HY-W022047

nNOS-IN-1 1 Publications Verification	NO Synthase	Cardiovascular Disease Neurological Disease
nNOS-IN-1(Compound 14) is an inhibitor for nitric oxide synthases (NOS), that exhibits inhibitory activities against neuroal, inducible and endothelial NOS, with IC₅₀s of 2.5, 5.7 and 13 μM, respectively .

HY-W007524

2-Aminoquinoline 1 Publications Verification 2-Quinolinamine	NO Synthase Orthopoxvirus	Infection Neurological Disease
2-Aminoquinoline (2-Quinolinamine) is a promising compound as bioavailable nNOS inhibitor but suffers from low human nNOS inhibition, low selectivity versus human eNOS, and significant binding to other CNS targets. 2-Aminoquinoline exhibits antiviral activity against the vaccinia virus. 2-Aminoquinoline has the potential for the research of antineurodegenerative agents .

HY-135224

1,4-PBIT dihydrobromide 1,4-PB-ITU dihydrobromide	NO Synthase	Cancer
1,4-PBIT (1,4-PB-ITU) dihydrobromide (compound 46) is a potent nitric oxide synthases (NOS) inhibitor, with K_i values of 7.6 nM, 360 nM, and 16 nM for the inducible (iNOS), endothelial (eNOS), and neuronal (nNOS) isozymes, respectively .

HY-101316

TRIM	NO Synthase	Neurological Disease
TRIM is a potent nitric oxide synthase inhibitor. TRIM inhibits mouse cerebellar nNOS and rat lung iNOS in vitro with IC₅₀ values of 28.2 and 27.0 µM, respectively. Antidepressant- and anxiolytic-like effects .

HY-101175

3-Bromo-7-nitroindazole 1 Publications Verification	NO Synthase	Neurological Disease Metabolic Disease
3-Bromo-7-nitroindazole is a potent and selective inhibitor of neuronal nitric oxide synthase (nNOS). 3-Bromo-7-nitroindazole affects the intercellular messenger nitric oxide (NO) synthesis throughout the body and brain. 3-Bromo-7-nitroindazole can be used for the researches of metabolic and neurological disease, such as diabetes, stroke and depression .

HY-130452

NOS1-IN-1	NO Synthase	Neurological Disease
NOS1-IN-1 is a selective and cell-permeable *nNOS* inhibitor with a K_i of 120 nM. NOS1-IN-1 exhibits 2617-fold and 325-fold selectivity over eNOS (K_i=39 μM) and iNOS (K_i=325 μM) , respectively . NOS1-IN-1 can be used for the research of neurological disease, including cerebral palsy (CP) .

HY-108960

PPADS	P2X Receptor Interleukin Related	Neurological Disease
PPADS is a P2X receptor (P2X Receptor) antagonist and a reversible competitive antagonist of NAADP receptors, with IC₅₀ values of 68 nM (P2X1) and 214 nM (P2X3), respectively. PPADS alleviates pain-related behaviors in the central and peripheral nervous systems of mice after peripheral neuropathy, inhibits the overproduction of IL-1β, IL-6, iNOS and *nNOS, and suppresses the hydrolytic activity of extracellular ATPase. PPADS blocks ATP-mediated inward currents on recombinant rat P2X₁* and P2X₃ receptors, and inhibits purinergic nerve stimulation-induced contraction of rabbit bladder detrusor muscle. PPADS is applicable to research related to neuropathic pain .

HY-P0117A

Tat-NR2B9c TFA 5+ Cited Publications Tat-NR2Bct TFA; NA-1 TFA	iGluR NO Synthase	Neurological Disease
Tat-NR2B9c TFA (Tat-NR2Bct TFA) is a postsynaptic density-95 (PSD-95) inhibitor, with EC₅₀ values of 6.7 nM and 670 nM for PSD-95d2 (PSD-95 PDZ domain 2) and PSD-95d1, respectively. Tat-NR2B9c TFA disrupts the PSD-95/NMDAR interaction, inhibiting NR2A and NR2B binding to PSD-95 with IC₅₀ values of 0.5 μM and 8 μM, respectively. Tat-NR2B9c TFA also inhibits neuronal nitric oxide synthase (nNOS)/PSD-95 interaction, and possesses neuroprotective efficacy .

HY-RS09433

NOS1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
NOS1 Human Pre-designed siRNA Set A contains three designed siRNAs for NOS1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NOS1 Human Pre-designed siRNA Set A NOS1 Human Pre-designed siRNA Set A

HY-138564

NOS-IN-1	NO Synthase	Inflammation/Immunology
NOS-IN-1 is a potent and orally active NO synthase (NOS) isoforms inhibitor with IC₅₀s of 0.1 μM, 1.1 μM, and 0.2 μM for human iNOS (hiNOS), heNOS and hnNOS, respectively .

HY-100986B

L-NIO	NO Synthase	Cardiovascular Disease
L-NIO is a potent, non-selective and NADPH-dependent nitric oxide synthase (NOS) inhibitor, with K_is of 1.7, 3.9, 3.9 μM for neuronal (nNOS), endothelial (eNOS), and inducible (iNOS), respectively . L-NIO induces a consistentfocal ischemic infarctin rats .

HY-147306

ZLc-002	NO Synthase	Neurological Disease
ZLc-002 is a selective inhibitor of *nNOS-Capon* coupling. ZLc-002 suppresses inflammatory nociception and chemotherapy-induced neuropathic pain. ZLc-002 can be used for the research of anxiety disorder and inflammation .

HY-19230

DY-9760e	Calmodulin NO Synthase CaMK Calcineurin Proteasome Caspase	Cardiovascular Disease
DY-9760e is a calmodulin (CaM) inhibitor. DY-9760e selectively inhibits the activity of various calmodulin-dependent enzymes by antagonizing the Ca²⁺/CaM complex, exhibiting the strongest inhibitory activity against *nNOS, CaM kinase II, and calcineurin* (K_i: 0.9, 1.4, and 2.0 μM, respectively). DY-9760e inhibits excessive nitric oxide production and protein tyrosine nitration, as well as the activation of calpain and caspase-3. DY-9760e reduces infarct size, improves cardiac function, and inhibits oxidative stress and cell death. DY-9760e can be used in research on the treatment of myocardial infarction, cerebral ischemia, and other diseases .

HY-W007524R

2-Aminoquinoline (Standard) 2-Quinolinamine (Standard)	Reference Standards NO Synthase Orthopoxvirus	Infection Neurological Disease
2-Aminoquinoline (2-Quinolinamine) is a promising compound as bioavailable nNOS inhibitor but suffers from low human nNOS inhibition, low selectivity versus human eNOS, and significant binding to other CNS targets. 2-Aminoquinoline exhibits antiviral activity against the vaccinia virus. 2-Aminoquinoline has the potential for the research of antineurodegenerative agents .

HY-W115558

L-Serine-O-sulfate potassium	Serine Racemase (SR)	Neurological Disease
L-Serine-O-sulfate potassium is a serine racemase (Srr) inhibitor. L-Serine-O-sulfate potassium attenuates the chronic constriction injury (CCI)-induced increases in NO levels, nNOS phosphorylation at Ser847, PKC-dependent GluN1 phosphorylation at Ser896, and the development of mechanical allodynia in mice. L-Serine-O-sulfate potassium can be used for the research of peripheral neuropathy .

HY-14343

KLYP961	NO Synthase	Neurological Disease
KLYP961 is a selective and orally active dual inhibitor of inducible and neuronal NO synthase (IC₅₀ = 50-400 nM). KLYP961 can inhibit endotoxin-evoked plasma nitrates increases and attenuate pain behaviors in a mouse formalin model. KLYP961 can attenuate carrageenin-induced edema and inflammatory hyperalgesia and writhing response elicited by Phenylbenzoquinone (HY-W275039). KLYP961 can be used for the research of neurological disease .

HY-147306A

(S)-ZLc002	NO Synthase	Neurological Disease
(S)-ZLc002 is a S-enantiomer of ZLc-002. ZLc-002 is a selective inhibitor of nNOS-Capon coupling. ZLc-002 suppresses inflammatory nociception and chemotherapy-induced neuropathic pain .

HY-122060

BYK 191023	NO Synthase	Metabolic Disease
BYK 191023 is a selective and L-arginine competitive inducible nitric-oxide synthase inhibitor with an IC₅₀ value of 86 nM, 17 µM, 162 µM for inducible (iNOS), neuronal (nNOS), and endothelial (eNOS) NO synthases respectively .

HY-P11222

Tat-SERT-15C	Serotonin Transporter NO Synthase	Neurological Disease
Tat-SERT-15C is a peptide. Tat-SERT-15C decreases the *SERT-nNOS* complex and increases SERT. Tat-SERT-15C reverses chronic unpredictable mild stress-caused depression behaviors .

HY-170236

nNOS-IN-5	NO Synthase	Neurological Disease
nNOS-IN-5 (Compound 9) is a potent human neuronal NOS (nNOS) inhibitor (K_i = 22 nM). nNOS-IN-5 exhibits excellent selectivity, with a 900-fold preference for human nNOS over human endothelial NOS (eNOS). nNOS-IN-5 can be used for neurodegenerative diseases study, such as Alzheimer's disease and Parkinson’s disease .

HY-115750

Nω-allyl-L-arginine	NO Synthase	Neurological Disease
Nω-allyl-L-arginine is a competitive and reversible inhibitor of bovine brain nitric oxide synthase (nNOS). Nω-allyl-L-arginine can inactivate nNOS in a time-dependent manner. Nω-allyl-L-arginine also is a substrate, producing L-arginine, acrolein, and H₂O .

HY-115410

NG-Amino-L-arginine hydrochloride	NO Synthase	Metabolic Disease
NG-Amino-L-arginine hydrochloride induces inactivation of the citrulline-forming activity of the *nNOS, iNOS, and eNOS* isoforms with K_i values of 0.3 μM, 3 μM, and 2.5 μM, respectively .

HY-124996

(Rac)-ZLc-002	NO Synthase	Neurological Disease Inflammation/Immunology Cancer
(Rac)-ZLc-002, an inhibitor of *nNOS* interaction with nitric oxide synthase 1 adaptor protein (NOS1AP), suppresses inflammatory nociception and chemotherapy-induced neuropathic pain and synergizes with Paclitaxel (HY-B0015) to reduce tumor cell viability .

HY-100458

SCR-4026	NO Synthase	Neurological Disease
SCR-4026 is a neuroprotective agent with blood-brain barrier penetration ability. SCR-4026 exerts neuroprotective effects by disrupting the interaction between neuronal *nNOS* and PSD9, with an IC₅₀ of 6.3 μM. SCR-4026 alleviates N-methyl-D-aspartate (NMDA)-induced excitotoxic damage in primary cortical neurons, and also protects neurons in the oxygen-glucose deprivation (OGD) model. SCR-4026 can reduce the cerebral infarct volume in the rat middle cerebral artery occlusion (MCAO) reperfusion model. SCR-4026 can be used for the study of stroke .

HY-RS09434

Nos1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Nos1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Nos1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Nos1 Mouse Pre-designed siRNA Set A Nos1 Mouse Pre-designed siRNA Set A

HY-W484263

hnNOS-IN-3	NO Synthase	Neurological Disease
hnNOS-IN-3 (compound 39) is a selective *nNOS* inhibitor, with a K_i of 0.32 μM. The nNOS binding of hnNOS-IN-3 is competitive with L-arginine. The selectivity of hnNOS-IN-3 for nNOS versus iNOS (K_i=37 μM) and eNOS (K_i=9.4 μM) is 115-fold and 29-fold, respectively .

HY-155355

LY836	iGluR	Neurological Disease
LY836 is an orally active neuroprotective agent. LY836 significantly blocks *PSD95-nNOS* association in cortical neurons. LY836 can be used in study ischemic stroke .

HY-P10029

Sakura-6	Serotonin Transporter	Neurological Disease
Sakura-6 is a SERT-nnos interaction promoter that significantly increases the SERT-nnos complex, but reduces the level of SERT on the cell surface. Acute injection of Sakura-6 into the dorsal raphe nucleus (DRN) causes depression-like behavior in mice .

HY-139135

Methyl-L-NIO hydrochloride	NO Synthase	Others
Methyl-L-NIO (compound 2d) hydrochloride is a potential selective inhibitor (IC₅₀: 70 μM) of dimethylarginine dimethylaminohydrolase hDDAH. Methyl-L-NIO also has inhibitory activity against NO synthase. The inhibition rates of Methyl-L-NIO on different isoforms of NO synthase at a concentration of 100 μM are 77% (nNOS), 20% (eNOS), and 72% (iNOS) respectively; the inhibition rates at a concentration of 1 mM are 100% (nNOS), 85% (eNOS), 100% (iNOS) .

HY-181711

nNOS-IN-6	NO Synthase	Neurological Disease Cancer
nNOS-IN-6 is a human neuronal nitric oxide synthase (hnNOS) inhibitor with a human hnNOS K_i of 16 nM, ~1800-fold selectivity over human eNOS, ~2900-fold selectivity over human iNOS, and a rat nNOS K_i of 34 nM.nNOS-IN-6 exhibits high effective permeability in PAMPA-BBB assays, crosses the blood-brain barrier, and shows sustained systemic exposure, low clearance, and robust brain penetration in mouse in vivo pharmacokinetic studies.nNOS-IN-6 can be used for the research of neurodegenerative diseases, melanoma .

HY-172764

L-ENIPO hydrochloride	NO Synthase	Metabolic Disease
L-ENIPO (hydrochloride) is an inhibitor of iNOS, *nNOS, and eNOS* with K_i values of 17, 10.3, and 58.2 μM. L-ENIPO (hydrochloride) exerts reversible tight binding inhibition selective for iNOS with longer incubation time .

Cat. No.	Product Name	Target	Research Area

HY-P0117

Tat-NR2B9c 5+ Cited Publications Tat-NR2Bct; NA-1	iGluR NO Synthase	Neurological Disease
Tat-NR2B9c (Tat-NR2Bct; NA-1) is a postsynaptic density-95 (PSD-95) inhibitor, with EC₅₀ values of 6.7 nM and 670 nM for PSD-95d2 (PSD-95 PDZ domain 2) and PSD-95d1, respectively. Tat-NR2B9c disrupts the PSD-95/NMDAR interaction, inhibiting NR2A and NR2B binding to PSD-95 with IC₅₀ values of 0.5 μM and 8 μM, respectively. Tat-NR2B9c also inhibits neuronal nitric oxide synthase (nNOS)/PSD-95 interaction, and possesses neuroprotective efficacy .

HY-P0117A

Tat-NR2B9c TFA 5+ Cited Publications Tat-NR2Bct TFA; NA-1 TFA	iGluR NO Synthase	Neurological Disease
Tat-NR2B9c TFA (Tat-NR2Bct TFA) is a postsynaptic density-95 (PSD-95) inhibitor, with EC₅₀ values of 6.7 nM and 670 nM for PSD-95d2 (PSD-95 PDZ domain 2) and PSD-95d1, respectively. Tat-NR2B9c TFA disrupts the PSD-95/NMDAR interaction, inhibiting NR2A and NR2B binding to PSD-95 with IC₅₀ values of 0.5 μM and 8 μM, respectively. Tat-NR2B9c TFA also inhibits neuronal nitric oxide synthase (nNOS)/PSD-95 interaction, and possesses neuroprotective efficacy .

HY-P11222

Tat-SERT-15C	Serotonin Transporter NO Synthase	Neurological Disease
Tat-SERT-15C is a peptide. Tat-SERT-15C decreases the *SERT-nNOS* complex and increases SERT. Tat-SERT-15C reverses chronic unpredictable mild stress-caused depression behaviors .

HY-P10029

Sakura-6	Serotonin Transporter	Neurological Disease
Sakura-6 is a SERT-nnos interaction promoter that significantly increases the SERT-nnos complex, but reduces the level of SERT on the cell surface. Acute injection of Sakura-6 into the dorsal raphe nucleus (DRN) causes depression-like behavior in mice .

HY-175824

*PSD-95/nNOS* PPI-IN-1**	iGluR NO Synthase Apoptosis Reactive Oxygen Species (ROS)	Neurological Disease
PSD-95/nNOS PPI-IN-1 is a inhibitor targeting the *PSD-95/nNOS* interaction with potential blood-brain barrier penetration. PSD-95/nNOS PPI-IN-1 binds to the PSD-95 PDZ2 domain with high affinity (K_i = 19.45 μM). PSD-95/nNOS PPI-IN-1 inhibits glutamate-induced excitotoxicity by reducing intracellular ROS levels and inhibiting apoptosis. PSD-95/nNOS PPI-IN-1 significantly reduces cerebral infarct volume in rat tMCAO models. PSD-95/nNOS PPI-IN-1 can be used for the study of acute ischemic stroke .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-18732A

L-NMMA acetate 10+ Cited Publications Tilarginine acetate; Methylarginine acetate	Cardiovascular Disease Natural Products Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification Cancer	NO Synthase Endogenous Metabolite
L-NMMA acetate is a nitric oxide synthase inhibitor of all NOS isoforms including NOS1, NOS2, and NOS3. The K_i values for nNOS (rat), eNOS (human), and iNOS (mouse) are approximately 0.18, 0.4, and 6 μM, respectively.

HY-14602

Tramiprosate 2 Publications Verification Homotaurine; 3-Amino-1-propanesulfonic acid	Microorganisms other families Classification of Application Fields Ketones, Aldehydes, Acids Plants Disease Research Fields Source Classification Cancer	Amyloid-β
Tramiprosate (Homotaurine), an orally active and brain-penetrant natural amino acid found in various species of red marine algae. Tramiprosate binds to soluble Aβ and maintains Aβ in a non-fibrillar form. Tramiprosate is also a GABA analog and possess neuroprotection, anticonvulsion and antihypertension effects .

HY-18732AR

L-NMMA acetate (Standard) Tilarginine acetate (Standard); Methylarginine acetate (Standard)	Structural Classification Natural Products Endogenous metabolite Source Classification	NO Synthase Endogenous Metabolite Reference Standards
L-NMMA (acetate) (Standard) is the analytical standard of L-NMMA (acetate). This product is intended for research and analytical applications. L-NMMA acetate is a nitric oxide synthase inhibitor of all NOS isoforms including NOS1, NOS2, and NOS3. The Ki values for nNOS (rat), eNOS (human), and iNOS (mouse) are approximately 0.18, 0.4, and 6 μM, respectively.

HY-14602R

Tramiprosate (Standard) Homotaurine (Standard); 3-Amino-1-propanesulfonic acid (Standard)	Structural Classification Microorganisms other families Ketones, Aldehydes, Acids Plants Source Classification	Reference Standards Amyloid-β
Tramiprosate (Standard) is the analytical standard of Tramiprosate. This product is intended for research and analytical applications. Tramiprosate (Homotaurine), an orally active and brain-penetrant natural amino acid found in various species of red marine algae. Tramiprosate binds to soluble Aβ and maintains Aβ in a non-fibrillar form. Tramiprosate is also a GABA analog and possess neuroprotection, anticonvulsion and antihypertension effects .

Cat. No.	Product Name	Chemical Structure

HY-B0503S

2-Thiouracil-13C,15N2
2-Thiouracil- ¹³C, ¹⁵N₂ is the ¹³C, ¹⁵N labeled 2-Thiouracil. 2-Thiouracil (Thiouracil) is an antithyroid compound. 2-Thiouracil can function as a highly specific melanoma seeker. 2-Thiouracil is a selective inhibitor of neuronal nitric oxide synthase (nNOS) with a Ki of 20 μM.

Host:	Rabbit (2)
Reactivity:	Human (1) Rat (2) Mouse (2)
Application:	IHC-P (1) ICC/IF (1) IP (1) WB (2)
Isotype:	IgG (2)
Conjugation:	Non-conjugated (2)
Clonality:	Monoclonal (2) Recombinant (2)
Modification:	Unmodified (2)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P80249

	nNOS Antibody (YA263) 1 Publications Verification	WB, IHC-P, ICC/IF, IP	Human, Mouse, Rat
	nNOS Antibody (YA263) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to nNOS.

HY-P87509

	nNOS Antibody (YA7193)	WB	Mouse, Rat
	nNOS Antibody (YA7193) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to nNOS.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks